# A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

> **NCT04824924** · PHASE2 · UNKNOWN · sponsor: **Shanghai Jiao Tong University School of Medicine** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** The combination of HHT, venetoclax, AZA, G-CSF

## Key facts

- **NCT ID:** NCT04824924
- **Lead sponsor:** Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03
- **Primary completion:** 2024-03
- **Final completion:** 2024-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824924, "A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04824924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*